期刊文献+

间接比较亚裔人群Ⅱ~Ⅲ期胃癌D2根治术后的辅助化疗方案 被引量:6

Indirect comparison of different adjuvant chemotherapies for stage II-III gastric cancer after D2 gastrectomy in Asian patients
原文传递
导出
摘要 目的间接比较亚裔人群Ⅱ-Ⅲ期胃癌D2根治术后不同辅助化疗方案的疗效。方法通过数据库电子检索以及手工检索相关文献,选择Ⅱ-Ⅲ期亚裔胃癌D2根治术后辅助化疗与单纯手术治疗比较的前瞻性随机对照临床试验(RCT)。选择总生存率和无病生存率为研究终点指标,通过Bucher校正间接比较法比较不同辅助化疗方案的疗效。结果2项研究纳入分析,1项研究涉及替吉奥(S.1)辅助化疗与单纯手术比较,1项研究涉及XELOX方案(奥沙利铂加卡培他滨)辅助化疗与单纯手术比较。间接比较结果显示,S-1与XELOX方案对总生存率影响的差异无统计学意义(HR=0.94,95%CI:0.62~1.44,P=0.79)。S-1较XELOX方案复发风险略有增加.但差异无统计学意义(HR=1.11,95%CI:0.80~1.53,P=0.54)。结论亚裔人群胃癌D2根治术后,S-1单药与XELOX方案辅助化疗疗效近似。 Objective To compare efficacy of different adjuvant chemotherapy regimens for stage II- III gastric cancer after D2 gastrectomy in Asian patients. Methods Associated literatures were searched through electronic databases and hand-searching. Prospective randomized clinical trials(RCTs) comparing adjuvant chemotherapy after D2 gastrectomy with surgery alone were included in the study. Overall survival and disease-free survival were chosen as the endpoints. Relative hazard was analyzed by Bucher adjusted indirect comparison. Results Two RCTs were selected, including comparison between S-1 versus surgery alone and comparison between XELOX versus surgery alone. There was no statistical difference in overall survival between the two regimens (HR=0.94, 95%CI:0.62-1.44, P=0.79). The recurrence risk of S-1 was slightly higher as compared to XELOX, but no statistical difference was found (HR=I.ll, 95%CI:0.80-1.53, P=0.54). Conclusion The adjuvant chemotherapy with S-1 is similar to XELOX for stage II- III gastric cancer after D2 gastrectomy in Asian patients.
出处 《中华胃肠外科杂志》 CAS CSCD 2013年第6期534-537,共4页 Chinese Journal of Gastrointestinal Surgery
关键词 胃肿瘤 辅助化疗 治疗效果 间接比较 Stomach neoplasms Adjuvant chemotherapy Treatment outcomes Indirect comparison
  • 相关文献

参考文献13

  • 1Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010,127:2893-2917.
  • 2Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch DID2 trial. Lancet Oncol, 2010,11:439-449.
  • 3Okines A, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up. Ann Oncol, 2010,21 :v50-v54.
  • 4Bang YJ, Kim YW, Yang HK, et al. Adjuvant eapeeitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC) : a phase 3 open-label, randomised controlled trial. Lancet, 2012,379:315-321.
  • 5Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase Ⅱ trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer. J Clin Oneol, 2011,29 : 4387-4393.
  • 6Nakajima T, Kinoshita T, Nashimoto A, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg, 2007,94 : 1468-1476.
  • 7Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouraeil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet, 1999,354: 273-277.
  • 8Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouraeil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Ontology Group 9206-1 J Clin Oneol, 2003,21:2282-2287.
  • 9Miyashiro I, Furukawa H, Sasako M, et al. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous eisplatin followed by oral fluorouraeil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer, 2011,14:212-218.
  • 10Kim HS, Jeung HC, Jung M, et al. Comparison of S-1 and eisplatin combination versus S-1 adjuvant chemotherapy for advanced gastric cancer. J Clin Oncol, 2012,30 suppl:e14652.

同被引文献37

  • 1万德森.临床肿瘤学[M].第2版.北京:科学出版社,2006:230-237.
  • 2Guggenheim DE,Shah MA.Gastric cancer epidemiology and risk factors.J Surg Oncol 2013;107:230-236.
  • 3Meyer HJ,Wilke H.Treatment strategies in gastric cancer.Dtsch Arztebl Int 2011;108:698-705;quiz 706.
  • 4Macdonald JS,Smalley SR,Benedetti J,Hundahl SA,Estes NC,Stemmermann GN,Haller DG,Ajani JA,Gunderson LL,Jessup JM,Martenson JA.Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.N Engl J Med 2001;345:725-730.
  • 5Cunningham D,Allum WH,Stenning SP,Thompson JN,Van de Velde CJ,Nicolson M,Scarffe JH,Lofts FJ,Falk SJ,Iveson TJ,Smith DB,Langley RE,Verma M,Weeden S,Chua YJ.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.N Engl J Med 2006;355:11-20.
  • 6Knight G,Earle CC,Cosby R,Coburn N,Youssef Y,Malthaner R,Wong RK.Neoadjuvant or adjuvant therapy for resectable gastric cancer:a systematic review and practice guideline for North America.Gastric Cancer 2013;16:28-40.
  • 7Taketa T,Sudo K,Wadhawa R,Blum MM,Ajani JA.Adjuvant therapy in gastric cancer:what is the optimal approach? Curr Oncol Rep 2013;15:146-151.
  • 8Park SC,Chun HJ.Chemotherapy for advanced gastric cancer:review and update of current practices.Gut Liver 2013;7:385-393.
  • 9Bang YJ,Kim YW,Yang HK,Chung HC,Park YK,Lee KH,Lee KW,Kim YH,Noh SI,Cho JY,Mok YJ,Kim YH,Ji J,Yeh TS,Button P,Sirzén F,Noh SH.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):a phase 3 open-label,randomised controlled trial.Lancet 2012;379:315-321.
  • 10Miura K,Shirasaka T,Yamaue H,Sasaki I.S-1 as a core anticancer fluoropyrimidine agent.Expert Opin Drug Deliv 2012;9:273-286.

引证文献6

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部